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Abstract
No major findings were reported at the 5
th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS
2009) on currently enrolled microbicides, pre-exposure prophylaxis (PrEP) or vaccine trials, although important find-
ings in all three areas of biomedical prevention research are expected within the next few years.
A study found that daily acyclovir did not reduce HIV transmission, but was a factor in modest reductions in viral
load, which could confer some clinical benefit. Research demonstrating rapid viral replication in mucosal tissue and
subsequent dissemination throughout the body suggested that research priorities should shift towards a mucosal
vaccine. Findings reported in Track C indicated that, in addition to reducing vertical transmission, antiretroviral ther-
apy (ART) also lowers the risk of prematurity, stillbirth and abortion.
Challenging concerns about the potential “disinhibiting” effect of ART as prevention, a Kenyan study found that
widespread ART encourages greater use of condoms and does not increase the rate of risky sex. Another Kenyan
study found that pregnancy increases the risk of HIV transmission in a cohort of serodiscordant couples. Although
three randomized trials have conclusively demonstrated that circumcision reduces HIV transmission among hetero-
sexual men, research presented at IAS 2009 found no evidence of a preventive impact for women.
Discussion
IAS 2009 included no major reports on three biomedical
prevention fronts (microbicides, PrEP and vaccines),
although important Phase III microbicide and PrEP
trials are under way and evidence is mounting regarding
t h ei m p a c to fA R Tr o l l o u to nr e d u c i n gH I Vt r a n s m i s -
sion (see Additional File 1). On the vaccine front, Track
C lead rapporteur Sinead Delany-Moretlwe [1] (Univer-
sity of Witwatersrand, Johannesburg) reviewed an analy-
sis by José Esparza (Bill & Melinda Gates Foundation,
Seattle), who noted that systemic immunity to HIV-1
rarely occurs in nature and may not be possible with a
vaccine [2]. Recent work demonstrating rapid viral repli-
cation in the mucosa and rapid systemic dissemination
suggests research priorities should shift to a mucosal
vaccine that elicits an immune response at the viral por-
tal of entry, Esparza argued. The meeting did feature
important studies on prevention with ART, circumcision
and acyclovir.
ART impact on pregnancy outcome and risky sex
Triple-drug ART does more than prevent vertical trans-
mission (as outlined in the Track B discussion); an
observational study of 3273 pregnant women in Malawi
and Mozambique showed that it also lowers the risk of
prematurity, abortion and stillbirth among African
women, providing additional insights into the benefits of
ART [3]. This study recorded significantly lower mortal-
ity among pregnant women who started nevirapine-
based ART than in those who did not (0.7% versus
7.4%, P <0.001).
* Correspondence: rkort@sympatico.ca
2Kort Consulting, Toronto, M4Y 2T6, Canada
Mascolinli and Kort Journal of the International AIDS Society 2010, 13(Suppl 1):S4
http://www.jiasociety.org/content/13/S1/S4
© 2010 Kort and Mascolinli; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Leonardo Palombi (DREAM Program, Rome) reported
that rates of abortion or stillbirth were 4.3% in the ART
group and 25.7% in the no-ART group (P <0.001).
Regardless of CD4 cell stratum, the prematurity rate
was 70.8% lower in women who took antiretrovirals.
A prospective study of 898 female bar workers in
Mombasa, Kenya, found no evidence supporting the
hypothesis that widespread ART will encourage more
risky sex in low-income countries. Indeed, women in
this cohort reported safer behaviour after they began
ART [4] than before they started. Linnet Masese (Uni-
versity of Nairobi) found significantly higher rates of
100% condom use after ART began and a strong trend
toward abstinence or having only one sex partner during
ART. Sexually transmitted infections were one-third less
likely after ART began.
Pregnancy doubles serodiscordant HIV transmission risk
Pregnancy doubled the risk of HIV transmission in a
two-year study of more than 500 HIV-discordant couples
(one positive partner, one negative partner) in Kisumu,
Kenya [5]. Sara Brubaker (University of California, San
Francisco) found that among 539 female partners (95% of
them married), 189 (35%) conceived. Forty-one of 539
uninfected partners (8%) became infected during the
study (see Figure 1). Among women who conceived or
men whose partners conceived, 10.8% became infected
during follow up, compared with 5.9% of partners who
did not have a child.
Those rates translated into a 1.8 times higher risk of
HIV infection in couples who had a child (P=0.046).
About 30% of new HIV infections happened six months
before conception, another 35% six months after con-
ception, and the remaining 35% more than six months
from conception. The presenting author noted that the
data did not determine intentionality to conceive and
that – if this is indeed the case – couples may be risking
a greater probability of HIV transmission in order to
conceive.
Circumcision and HIV risk in female partners
Three randomized trials conclusively demonstrate that
circumcision lowers risk of HIV acquisition in hetero-
sexual men, and circumcision programmes are being
rolled out in a number of countries in sub-Saharan
Africa (see Figure 2) [6-8]. But how the procedure
affects HIV risk in female partners remains unknown.
Results from two studies of serodiscordant couples (an
observational study presented at IAS 2009 and a rando-
mized controlled trial published in the scientific litera-
ture) could not establish that circumcision protects
female partners from HIV.
The prospective observational study weighed the risk
of HIV transmission in 1096 serodiscordant couples
Comparison of those who conceived with those who did not
Pregnancy
(N = 373)
No pregnancy
(N = 698) p-Value
Median age in years (IQR) 27 (24-32) 34 (27-44) <0.01
Median number (IQR) of 
children with study partner 1 (0-3) 2 (0-4) 0.01
Median number (IQR) of years 
with study partner 4 (2-7) 6 (2-7) <0.01
Percent of women HIV infected  56 63 0.10
Median CD4 count/mcL (IQR) 
of HIV infected partner 477 (349-615) 429 (331-623) 0.12
Percent of individuals who 
seroconverted
10.8 5.9 0.046
RR = 1.8
Figure 1 Pregnancy and the risk of HIV transmission. Source: Brubaker S, et al. Pregnancy and HIV transmission among HIV discordant
couples in a clinical trial in Kisumu, Kenya. 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention: Cape Town, South Africa.
WELBC105 [5].
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trial of acyclovir to prevent HIV transmission [9]. Dur-
ing one to two years of follow up at 14 sites across
Africa, 64 female partners became infected; viral sequen-
cing established the male partners as the source in 50 of
these women. One-third of the men were circumcised.
Jared Baeten (University of Washington, Seattle) found
that the overall new infection rate was 2.7 per 100 per-
son-years in female partners of circumcised men versus
4.4 in partners of uncircumcised men. Among newly
infected female partners whose HIV sequences matched
that of their partners, HIV incidence was 2.0 in partners
of circumcised men and 3.5 in partners of uncircum-
cised men. In both of these comparisons, the risk of
HIV infection adjusted for male viral load fell short of
statistical significance (P=0.13).
A trial that randomized HIV-infected Ugandan men to
immediate or deferred circumcision found no significant
difference in HIV incidence among partners of circum-
cised men (18%) and uncircumcised men (12%) [10].
The investigators note that their analysis cannot exclude
“the possibility of higher risk of transmission in couples
who resumed sexual intercourse before complete [cir-
cumcision] wound healing”.
Daily acyclovir and risk of HIV transmission or
progression
Two previously published placebo-controlled trials of
daily acyclovir found that this antiherpes drug does not
prevent HIV acquisition in women and men infected
with herpes simplex virus type 2 (HSV-2) [11,12]. A
trial presented at IAS 2009 found that daily acyclovir
does not prevent HIV transmission from HIV/HSV-2
infected people to their partners [13]. This trial, invol-
ving 3408 heterosexual HIV-discordant African couples
at 14 sites, randomized HIV-1/HSV-2 coinfected part-
ners to placebo or to 400mg of acyclovir twice daily.
Two-thirds of coinfected partners were female, no one
was taking antiretrovirals, and participants reported tak-
ing 96.5% of acyclovir doses.
Connie Celum (University of Washington, Seattle)
reported that after 24 months of follow up, 84 new
HIV-1 infections could be linked to study partners, 41
of them taking acyclovir and 43 taking placebo. Daily
acyclovir significantly lowered the frequency of HSV-2-
positive genital ulcers and reduced HIV load by an aver-
age 0.25 log, but those benefits were insufficient to
protect partners from HIV transmission.
Although the modest decline in viral load recorded in
this trial did not prevent coinfected partners from trans-
mitting HIV to their partners, even a small decline may
confer clinical benefits, according to secondary results of
another African study [14]. This placebo-controlled trial
involved 2284 women and 1097 men coinfected with
HIV-1 and HSV-2, but taking no antiretrovirals because
they had a CD4 count above 250 cells/mm
3.J a i r a mR
Lingappa (University of Washington, Seattle) found that
284 people taking acyclovir and 325 taking placebo
Figure 2 Progress on male circumcision. Source: Sinead Delany-Moretlwe: Track C Rapporteur Report. 5th IAS Conference on Pathogenesis,
Treatment and Prevention: Cape Town, South Africa. [1]
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200 cells/mm
3, ART initiation, or death from causes
other than trauma. Those numbers translated into a
27% lower risk of reaching the composite endpoint
(P=0.03).
Conclusions
The 3000-woman analysis demonstrating lower rates of
prematurity, abortion and stillbirth in women taking a
triple-antiretroviral combination [3] adds to the already
ample evidence supporting standard ART during preg-
nancy and breastfeeding. At this point, however, many
pregnant or breastfeeding women do not receive stan-
dard ART because they do not meet national treatment
criteria. In female Mombasa barmaids who reported
transactional sex, starting ART coincided with less high-
risk sexual behaviour [4], a finding suggesting that ART
does not have a “sexual disinhibiting” effect, at least in
this population. These results also confirm the feasibility
of bringing high-risk women into care.
The study finding a higher risk of HIV transmission in
HIV-discordant couples who have a child [5] indicates
that discordant partners may continue to conceive even
when they know one partner has HIV. If a portion of
these pregnancies were intentional, the investigators
suggest, these couples are risking HIV transmission in
order to conceive. The results emphasize the importance
of targeting serodiscordant married and unmarried cou-
ples in prevention initiatives.
Two studies failed to establish a lower risk of HIV
infection in female partners of circumcised versus
uncircumcised men [9,10]. The authors of the study
presented at IAS 2009 suggest “short term interven-
tions to protect against transmission risk during
wound healing after circumcision of HIV-1 infected
men could be considered, in order to realize the longer
term potential benefits of male circumcision” [9]. The
authors of a previously published randomized trial add
that protecting men from becoming infected by cir-
cumcising them probably lowers overall HIV transmis-
sion risk in a heterosexual population because it
lowers the proportion of men carrying HIV [10]. There
is no doubt that circumcision can be a valuable facet
of HIV prevention for heterosexual men. (There have
been no randomized trials of circumcision in men who
have sex with men.)
The acyclovir trials show that this antiherpes agent
has no role in preventing HIV transmission [13], but it
can help slow HIV disease progression in people not
taking ART [14]. The latter finding emphasizes the
importance of testing simple, inexpensive non-ART stra-
tegies, such as acyclovir and cotrimoxazole, in people
with HIV.
Track C lead rapporteur Sinead Delany-Moretlwe
drew four lessons from prevention studies presented at
the conference [1]:
￿ Treatment has progressed; prevention remains
challenging.
￿ Biomedical interventions still require behavioural
change; risk compensation needs to be monitored.
￿ The concept of treatment for prevention brings the
treatment and prevention worlds closer than ever
before.
￿ New interventions for prevention are most likely to
be effective when delivered in combination.
Additional file 1. New data on the preventive impact of
antiretroviral therapy: New data on the preventive impact of
antiretroviral therapy
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